Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Taxoids | 4 | 2017 | 665 | 1.360 |
Why?
|
Arthralgia | 3 | 2017 | 456 | 1.260 |
Why?
|
Bone Neoplasms | 7 | 2020 | 2525 | 1.120 |
Why?
|
Antiemetics | 5 | 2019 | 176 | 0.990 |
Why?
|
Nausea | 5 | 2019 | 668 | 0.900 |
Why?
|
Vomiting | 5 | 2019 | 635 | 0.890 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 59 | 0.850 |
Why?
|
Antihypertensive Agents | 6 | 2022 | 2047 | 0.760 |
Why?
|
Hypertension | 7 | 2022 | 8480 | 0.750 |
Why?
|
Palliative Care | 6 | 2020 | 3490 | 0.580 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 985 | 0.500 |
Why?
|
Blood Pressure | 6 | 2022 | 8551 | 0.490 |
Why?
|
Education | 1 | 2015 | 543 | 0.430 |
Why?
|
Glomerular Filtration Rate | 2 | 2021 | 2170 | 0.420 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2022 | 11732 | 0.420 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 623 | 0.420 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2021 | 2208 | 0.400 |
Why?
|
Cardiology | 1 | 2022 | 1668 | 0.390 |
Why?
|
Health Expenditures | 2 | 2022 | 2348 | 0.370 |
Why?
|
Pain Measurement | 3 | 2017 | 3419 | 0.360 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5755 | 0.340 |
Why?
|
Life Expectancy | 1 | 2015 | 1184 | 0.320 |
Why?
|
Insulin | 1 | 2022 | 6583 | 0.310 |
Why?
|
Medicare | 2 | 2022 | 6566 | 0.300 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1007 | 0.280 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3611 | 0.280 |
Why?
|
Benzodiazepines | 3 | 2016 | 1101 | 0.270 |
Why?
|
Pain | 2 | 2015 | 4987 | 0.230 |
Why?
|
Parenteral Nutrition | 2 | 2019 | 650 | 0.220 |
Why?
|
Models, Theoretical | 1 | 2015 | 3591 | 0.220 |
Why?
|
Curriculum | 1 | 2015 | 3604 | 0.210 |
Why?
|
Enteral Nutrition | 2 | 2019 | 763 | 0.210 |
Why?
|
Famotidine | 1 | 2021 | 16 | 0.210 |
Why?
|
Naphthyridines | 1 | 2022 | 118 | 0.200 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15161 | 0.190 |
Why?
|
Incretins | 1 | 2021 | 88 | 0.190 |
Why?
|
Glucagon-Like Peptides | 1 | 2021 | 127 | 0.190 |
Why?
|
Colchicine | 1 | 2021 | 243 | 0.190 |
Why?
|
Serotonin 5-HT3 Receptor Antagonists | 2 | 2019 | 18 | 0.180 |
Why?
|
Humans | 49 | 2023 | 744220 | 0.180 |
Why?
|
United States | 13 | 2023 | 69867 | 0.180 |
Why?
|
Clinical Competence | 1 | 2015 | 4687 | 0.180 |
Why?
|
Brain Neoplasms | 3 | 2016 | 8860 | 0.170 |
Why?
|
Rural Health | 1 | 2021 | 305 | 0.170 |
Why?
|
Neoplasms | 8 | 2019 | 21672 | 0.170 |
Why?
|
Hypotension, Orthostatic | 1 | 2022 | 255 | 0.170 |
Why?
|
Pulmonary Edema | 1 | 2022 | 414 | 0.170 |
Why?
|
Urban Health | 1 | 2021 | 547 | 0.160 |
Why?
|
Anti-Obesity Agents | 1 | 2021 | 216 | 0.160 |
Why?
|
Albuminuria | 1 | 2022 | 683 | 0.160 |
Why?
|
American Heart Association | 1 | 2022 | 1056 | 0.150 |
Why?
|
Radiosurgery | 2 | 2019 | 1328 | 0.150 |
Why?
|
Awards and Prizes | 1 | 2022 | 375 | 0.150 |
Why?
|
Patient Admission | 2 | 2021 | 1380 | 0.140 |
Why?
|
Patient Care | 1 | 2022 | 640 | 0.140 |
Why?
|
Prevalence | 6 | 2021 | 15226 | 0.130 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 3256 | 0.130 |
Why?
|
Breast Neoplasms | 3 | 2017 | 20817 | 0.130 |
Why?
|
Ondansetron | 1 | 2016 | 89 | 0.130 |
Why?
|
Drug Approval | 1 | 2021 | 741 | 0.130 |
Why?
|
Protein-Energy Malnutrition | 1 | 2016 | 187 | 0.130 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 450 | 0.120 |
Why?
|
Aged | 15 | 2022 | 163253 | 0.120 |
Why?
|
Quality of Life | 6 | 2017 | 12805 | 0.120 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13668 | 0.120 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2020 | 1240 | 0.120 |
Why?
|
Prognosis | 5 | 2019 | 29050 | 0.120 |
Why?
|
Methylprednisolone | 1 | 2016 | 388 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2021 | 9960 | 0.120 |
Why?
|
Retreatment | 1 | 2015 | 610 | 0.120 |
Why?
|
Cholesterol, LDL | 1 | 2023 | 2355 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2020 | 1531 | 0.120 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1583 | 0.110 |
Why?
|
Diabetes Complications | 1 | 2020 | 1361 | 0.110 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 2875 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20123 | 0.110 |
Why?
|
Heart Failure | 3 | 2022 | 10905 | 0.110 |
Why?
|
Cause of Death | 2 | 2021 | 3584 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 3842 | 0.100 |
Why?
|
Bone Remodeling | 1 | 2015 | 575 | 0.100 |
Why?
|
Middle Aged | 18 | 2021 | 213367 | 0.100 |
Why?
|
Intensive Care Units | 2 | 2021 | 3680 | 0.090 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 1677 | 0.090 |
Why?
|
Nutrition Surveys | 3 | 2022 | 1660 | 0.090 |
Why?
|
Female | 21 | 2021 | 380197 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1797 | 0.090 |
Why?
|
Obesity | 2 | 2022 | 12742 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 7908 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.090 |
Why?
|
Aged, 80 and over | 7 | 2021 | 57768 | 0.080 |
Why?
|
Cohort Studies | 2 | 2022 | 40559 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3158 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 1831 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1525 | 0.080 |
Why?
|
Dexamethasone | 1 | 2016 | 1948 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3952 | 0.080 |
Why?
|
Male | 19 | 2021 | 350027 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15538 | 0.080 |
Why?
|
Hospital Mortality | 1 | 2021 | 5316 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2020 | 3068 | 0.070 |
Why?
|
Radiation Dosage | 1 | 2015 | 1928 | 0.070 |
Why?
|
Risk Factors | 4 | 2023 | 72280 | 0.070 |
Why?
|
Adult | 12 | 2023 | 214035 | 0.070 |
Why?
|
Survival Rate | 1 | 2019 | 12781 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2023 | 6489 | 0.060 |
Why?
|
Registries | 1 | 2018 | 8090 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 3058 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10262 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2021 | 63119 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 3130 | 0.050 |
Why?
|
Histamine H2 Antagonists | 1 | 2021 | 165 | 0.050 |
Why?
|
Time Factors | 2 | 2019 | 40063 | 0.050 |
Why?
|
Hospitals, Rural | 1 | 2021 | 172 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 499 | 0.040 |
Why?
|
Risk | 2 | 2021 | 9685 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 4245 | 0.040 |
Why?
|
Incidence | 1 | 2017 | 20945 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2020 | 77426 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2020 | 243 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2012 | 4041 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2021 | 403 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9849 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39045 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5221 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4841 | 0.040 |
Why?
|
Cholesterol, HDL | 1 | 2023 | 1814 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11493 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1179 | 0.040 |
Why?
|
Prospective Studies | 2 | 2017 | 53280 | 0.030 |
Why?
|
Dyssomnias | 1 | 2015 | 29 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2022 | 1265 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12355 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 601 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1223 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1025 | 0.030 |
Why?
|
Dyspnea | 1 | 2022 | 1303 | 0.030 |
Why?
|
Nutritional Support | 1 | 2016 | 168 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 633 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1147 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1914 | 0.030 |
Why?
|
Drug Utilization | 1 | 2020 | 1183 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 1176 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11074 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2021 | 1411 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 173 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6172 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2018 | 2970 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13096 | 0.020 |
Why?
|
Nutritional Status | 1 | 2019 | 1609 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 7022 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
Paclitaxel | 1 | 2017 | 1707 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2389 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2864 | 0.020 |
Why?
|
Ultrasonography | 1 | 2022 | 5982 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2662 | 0.020 |
Why?
|
Infection Control | 1 | 2016 | 964 | 0.020 |
Why?
|
Fatigue | 1 | 2015 | 1531 | 0.020 |
Why?
|
Weight Loss | 1 | 2019 | 2622 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4929 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2603 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19907 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 3923 | 0.020 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2337 | 0.020 |
Why?
|
Body Mass Index | 1 | 2022 | 12718 | 0.020 |
Why?
|
Animals | 1 | 2016 | 168788 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10396 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6367 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5138 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10387 | 0.010 |
Why?
|
Lung | 1 | 2022 | 9852 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18367 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7784 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11728 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23337 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13280 | 0.010 |
Why?
|
Stroke | 1 | 2018 | 9981 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 56436 | 0.010 |
Why?
|
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_